Evidence map›Paper›PMID 38655709›Full record

ArticleJournal of cellular and molecular medicine2024

Retraction: miR-655 suppresses epithelial-to-mesenchymal transition by targeting Prrx1 in triple-negative breast cancer.

Abstract readRetraction Notice
In one paragraph

Article in Journal of cellular and molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

0 authors.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zhi-Dong Lv, Bin Kong, Xiang-Ping Liu, Li-Ying Jin, Qian Dong, Fu-Nian Li, Hai-Bo Wang, miR-655 suppresses epithelial-to-mesenchymal transition by targeting Prrx1 in triple-negative breast cancer. Journal of Cellular and Molecular Medicine, 20: 864-873. https://doi.org/10.1111/jcmm.12770 The above article, published online on 28 January 2016 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the journal Editor-in-Chief, Stefan Constantinescu, The Foundation for Cellular and Molecular Medicine, and John Wiley and Sons Ltd. In 2022, the authors asked to retract the article as they found that some images were mistakenly duplicated from their previously published papers. Subsequently, an investigation into concerns raised by a third party revealed inappropriate duplications and manipulation of images between this (Figures 2B,D, 3A, 5B, 6C,D and 7B) and five other articles (with the same first or corresponding author) that were published previously or in the same year in a different scientific context. Due to the number and the level of errors identified in the published figures, the editors consider the conclusions of this manuscript substantially compromised. Although the authors initially asked for the retraction, they did not agree to the retraction wording.

Identifiers

PMID38655709
PMCPMC11040458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.